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Abstract
Expression of eukaryotic proteins in Escherichia coli is challenging, especially when they contain disulfide bonds.
Since the discovery of the prion protein (PrP) and its role in transmissible spongiform encephalopathies, the need
to obtain large quantities of the recombinant protein for research purposes has been essential. Currently,
production of recombinant PrP is achieved by refolding protocols. Here, we show that the co-expression of two
different PrP with the human Quiescin Sulfhydryl OXidase (QSOX), a human chaperone with thiol/disulfide oxidase
activity, in the cytoplasm of E. coli produces soluble recombinant PrP. The structural integrity of the soluble PrP has
been confirmed by nuclear magnetic resonance spectroscopy, demonstrating that properly folded PrP can be
easily expressed in bacteria. Furthermore, the soluble recombinant PrP produced with this method can be used for
functional and structural studies.
Introduction
Prion diseases, also referred as transmissible spongiform
encephalopathies (TSEs), are a family of rare progressive
neurodegenerative disorders that affect both humans and
animals [1]. TSEs include, for instance, bovine spongiform
encephalopathy (BSE) in cattle, and Creutzfeldt-Jakob dis-
ease (CJD) in humans. These disorders are characterized
by long incubation periods and characteristic spongiform
changes in the brain associated with neuronal loss. The
causative agent of TSEs is an infectious protein known as
prion (also denoted as PrPSc) [2]. This pathogenic beta-
sheet-rich conformer derives from the normal, mostly
alpha-helical isoform, cellular prion protein (PrP or PrPC),
through a conformational conversion event which leads to
aggregates in the brains of affected individuals leading to
neurodegeneration [3].
Since the identification of prions as the causing agent of
TSEs, recombinant PrP has been instrumental to study the
structural and biophysical aspects of prion amyloidosis [4].
Due to its easy handling, inexpensive medium and
large-scale production, the enteric bacterium Escherichia
coli (E. coli) is the organism of choice for the production
of numerous recombinant proteins [5]. However, expres-
sion of mammalian proteins in E. coli remains difficult
and often results in inactive aggregates because the
recombinant proteins do not fold properly in this host
[6]. For example, recombinant PrP is largely expressed as
inclusion bodies [7]. Most refolding protocols require a
large amount of reagents and are time consuming.
Success is highly dependent on the experimenter’s
savoir-faire. Attempts to assist proper folding of the PrP
in the cytoplasm of E. coli by co-expression with bacterial
chaperones failed [8]. As the formation of a disulfide
bond is essential for PrP proper folding, expression of
full-length PrP in the periplasm of E. coli was also investi-
gated, resulting in soluble PrP which is partially degraded
at the unstructured N-terminal end [9]. It has been
observed that PrP can interact with several chaperones
from the endoplasmic reticulum (ER) [10], including
Pdia3 (also known as ERp57) and Grp58 (ERp60) [11],
suggesting that in physiological condition, PrP requires
assistance to fold into the correct conformation. In addi-
tion, PrP contains a disulfide bond which is crucial for
the proper a-helical fold [12]. Based on these observa-
tions, we investigated the use of QSOX as a folding cata-
lyst for PrP in the cytoplasm of E. coli. QSOX is a human
chaperone that introduces disulfide bonds in secreted
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proteins downstream of the ER [13], and has been shown
to be enzymatically active in the bacterial cytoplasm [14].
In the present study, we describe for the first time the
production of soluble PrP of both mouse (MoPrP) and
human (HuPrP) using co-expression with QSOX in the
E. coli cytoplasm.
Materials and methods
Plasmids Construction
Human PrP (HuPrP): full length (23-231) and
truncated (90-231)
Cloning of HuPrP(90-231) into pET-28a (Novagen) was
performed as described previously [15]. HuPrP(23-231)
was subcloned from the plasmid HuPrP(23-231)/pET-
11a [16] into pET-28a as BamHI-NdeI fragment using
the standard molecular biology techniques.
Mouse PrP(MoPrP): full length (23-230) and
truncated (89-230)
Cloning of MoPrP(23-230) and MoPrP(89-230) as
described previously [15].
QSOX
The human QSOX plasmid was a generous gift from
Prof. Colin Thorpe [13].
Protein expression
Small-scale expression trials
Each PrP construct and the QSOX plasmid were co-trans-
formed into E. coli Rossetta (DE3) pLysS and plated on
LB-agar supplemented with 100 μg/mL ampicillin and
25 μg/mL kanamycin. A single colony was used to inocu-
late a 25 mL pre-culture (LB medium supplemented with
100 μg/mL ampicillin and 25 μg/mL kanamycin). The fol-
lowing day, a 25 mL culture was inoculated with 1 mL of
the pre-culture. Cells were induced at A600 = 0.7 by adding
1 mM isopropyl-b-D-thiogalactopyranoside (IPTG). After
induction culture was incubated overnight (16 h) at 15°C.
Harvested cells were resuspended in lysis buffer: 0.1 g of
cell paste/mL of 50 mM potassium phosphate, pH 7.5,
300 mM NaCl supplemented with 0.1 mg/mL lysozyme,
0.1 mg/mL ABESF and 1 μg/mL leupeptin. The lysate was
sonicated 4 times, each 30 s at 4°C and was subsequently
centrifuged 20 min at 18,000 g. Supernatant was collected
and pellet was resuspended in initial volume using lysis
buffer. Total fraction, supernatant and pellet were ana-
lyzed for the presence of soluble PrP by SDS/PAGE and
immunoblotting.
Growth curve and quantification of PrP production
For plotting the growth curve of MoPrP(89-230) small-
scale cultures (MoPrP/QSOX and MoPrP/no QSOX) were
produced as described previously. Samples were collected
at 30 minutes time intervals and A600 was measured. Opti-
cal density was plotted versus time.
To quantify the amount of PrP produced at the differ-
ent times during the growth, 1 L culture was induced as
described earlier and 40 mL samples were collected at 0,
1, 2, 4, 8 and 16 h after induction. Cells were collected by
centrifugation at 15,000 g for 10 min, weighted and
resuspended in (0.1 g of cell paste/mL) volume of lysis
buffer to normalize the cell content for each time point.
For estimating the total prion production 4 μl were
mixed with 1 μl SDS loading buffer (5X) and boiled for 5
min. To determine the quantity of soluble expressed PrP,
resuspended cells were lysed by sonication and centri-
fuged at 18,000 g for 20 min. 4 μl of supernatant was
mixed with 1 μl SDS loading buffer (5X) and boiled for 5
min. Collected samples were analyzed on SDS-PAGE and
by immunoblotting. Intensity of the blot signals was
quantified using the software LabImage 1D Gel Analysis
(Kapelan GmbH, Germany).
Immunoblotting
Mouse monoclonal anti-His antibody was purchased
from Sigma Aldrich, Belgium. Proteins analyzed on SDS-
PAGE were transferred to nitrocellulose membranes
(MACHEREY-NAGEL) and bands were visualized by
goat anti-mouse IgG, alkaline phosphatase conjugate
(Sigma) using NBT/BCIP as substrate (Roche Diagnos-
tics, GmbH, Germany).
Large-scale protein expression and purification
MoPrP(89-230), HuPrP(90-231), MoPrP(23-230) and
HuPrP(23-231) were co-expressed with QSOX in E. coli
Rossetta (DE3) pLysS. Expression up-scaling was carried
out as follows. Pre-cultures (25 mL) were grown overnight
at 37°C in LB medium supplemented with 100 μg/mL
ampicillin and 25 μg/mL kanamycin. 10 mL of pre-culture
were used to inoculate 1 L of LB medium supplemented
with ampicillin and kanamycin. Cells were induced at
A600 = 0.7 by adding 1 mM isopropyl-b-D-thiogalactopyr-
anoside (IPTG) and temperature was shifted to 15°C for
16 h.
Cells were harvested by centrifugation (15 min at 15,000
g). Cells pellets were re-suspended as 0.1 g of cell paste/mL
in 50 mM potassium phosphate, pH 7.5, 300 mM NaCl
supplemented with 0.1 mg/mL lysozyme, 0.1 mg/mL
AEBSF and 1 μg/mL leupeptin. Cells were disrupted two
times with a French press (10,000 psi) and followed by cen-
trifugation at 4°C for 60 min at 40,000 g. The collected
supernatant was loaded on a 5 mL Histrap Ni-NTA col-
umn (GE-healthcare) previously equilibrated with 50 mM
potassium phosphate pH 7.5, 300 mM NaCl, 10 mM imi-
dazole. The column was washed with five column volumes
(CV) of washing buffer: 50 mM potassium phosphate pH
7.5, 1 M NaCl, 50 mM imidazole, followed by ten CV of
50 mM potassium phosphate pH 6.0, 1 M NaCl, 50 mM
imidazole. The protein was eluted with a gradient of
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imidazole from 50 mM to 1 M in 50 mM potassium phos-
phate pH 7.5. The elution peak fractions were loaded on a
SDS/PAGE to evaluate purity, then pooled, and concen-
trated for a second purification step. Size exclusion chro-
matography was performed in 20 mM Tris-HCl pH 7.5
with 150 mM NaCl on a Superdex75 HR 10/30 (GE
Healthcare). The elution peak was again loaded on SDS/
PAGE and collected for a dialysis against 10 mM sodium
acetate pH 4.6, 1 mM EDTA followed by the final dialysis
buffer of 10 mM sodium acetate pH 4.6. Protein aliquots
were stored at -80°C until further usage.
Circular dichroism (CD) experiments
CD spectra were recorded at 25°C using a spectropolari-
meter (Jasco, model 715, Tokyo, Japan). The purified pro-
tein was diluted in water to the final concentration of
0.2 mg/mL. CD spectra were acquired at a scan speed of
50 nm/min, 1 nm bandwidth and a response time of 1 s.
A 0.01 cm path length quartz cells was used to record
spectra of the different proteins in the far ultraviolet
region (190-260 nm), each spectrum was recorded
4 times. The sample and the buffer solutions were purged
with dry nitrogen.
Nuclear magnetic resonance (NMR) measurements
Uniformly 15N and both 15N and 13C-labeled MoPrP(89-
230) were produced in M9 minimal medium supplemen-
ted with 15NH4Cl and [
13C] glucose as described by
Marley et al. [17]. The labelled proteins were purified as
described above for unlabelled proteins.
The NMR experiments were recorded on 15N, 13C-
labeled MoPrP(89-230) concentrated to approximately
0.5 mM into 10 mM sodium acetate buffer pH 4.6. Two
dimensional NMR 15N and 13C heteronuclear single
quantum correlation (HSQC) spectra and three dimen-
sional NMR experiments CBCA(CO)NH, HNCACB,
HNCO, HBHA(CO)NH were performed at 293 K on
MoPrP(89-230) on a Varian NMR Direct-Drive Systems
800 MHz spectrometer equipped with a salt tolerance tri-
ple-resonance PFG-Z cold probe. Sequence specific back-
bone 1HN, 15N, 13C’, 13Ca, 13Cb, Ha and Hb chemical
shifts were determined using standard triple-resonance
assignment methodology [18]. Identical experiments
were performed for MoPrP(89-230) at pH 7.0. All the
NMR data were processed with NMRPipe 2.1 software
[19] and analysed using CCPNmr Analysis 2.0 [20].
CS23D2.0 [21] was used to generate a 3D model of
MoPrP(89-230) at pH 4.6 using only the backbone che-
mical shifts.
Thiostar assay
The thiostar assay determines accurately the amount of
free thiol content in samples [22]. To perform this assay,
we used the kit Detect X™, Luminos (Arbor assays,
USA). A standard curve was plotted using reduced
L-glutathion (Sigma, Belgium) at different concentrations
(0 μM, 10 μM, 20 μM, 30 μM, 40 μM, 50 μM and
60 μM). Two protein samples were tested: soluble PrP
and refolded, both samples were tested at a fixed concen-
tration of 5 μM. All standards and samples were diluted
10 times in a thiol-free buffer to a final volume of 100 μL
in a 96-well plate. Then we added 15 μL of Thiostar
reagent to each well. After mixing, we incubated the
plate at room temperature for 30 min in the dark. The
fluorescent product was measured at 510 nm in a fluores-
cent plate-reader (Infinite M200, TECAN) with excita-
tion at 390 nm.
Amyloid seeding assay (ASA) protocol
MoPrP(89-230) has been diluted to 0.1 mg/mL in phos-
phate-buffered saline (PBS) solution containing 0.4 M
Guanidine hydrochloride (GuHCl), 10 mM Thioflavin T
(ThT). The fibrilization reaction was performed in a final
volume of 200 μL in 96-well plate (BD Falcon, BD
Bioscience). For seeding experiment we performed the
amyloid seeding assay (ASA) according to Colby et al.,
2007 [23] with some minor modifications. Briefly, 1 mg of
ScGT1 cell lysate were used for PTA precipitation by add-
ing 500 μL of PBS containing 4% sarkosyl, protease inhibi-
tor (Complete, Roche) and 0.5% PTA, with continuous
shaking at 37°C, 350 rpm for 1 h and centrifuged 14,000 g
for 30 min. The pellet was washed and resuspended in the
previous buffer, then centrifuged again and re-suspended
in 150 μL of sterile double distilled H2O. In ASA, 4 μL of
re-suspended PTA pellet were diluted in 400 μL of water
and 20 μL of diluted sample were added to each well. The
plate was incubated at 37°C with continuous shaking on a
plate reader (Spectramax M5, Molecular Device). The
kinetics of fibril formation was monitored by top reading
of fluorescence intensity every 5 min at 444 nm excitation
and 485 nm emission.
Conversion of the monomeric MoPrP into amyloid fibrils
MoPrP(89-230) was diluted into 50 mM phosphate buffer,
2 M GuHCl, pH 6.5 to a final concentration of 0.4 mg/ml
and incubated at 37°C with constant rotation (8 rpm).
Atomic Force Microscopy (AFM)
The converted PrP samples were incubated on a freshly
cleaved mica surface for approximately 30 seconds and
subsequently rinsed with water to remove salts and
unbound protein. After drying the samples were imaged
using tapping mode on a Digital Instruments Multimode
atomic force microscope equipped with Nanoscope IV
controller and a type E scanner. All images were
acquired using single-beam silicon probes with a nom-
inal spring constant of 40 N/m and nominal tip radius
of 10 nm.
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X-ray fiber diffraction
Converted PrP was pelleted by centrifugation at 16,000 g,
and pellet was subsequently washed twice with water to
remove salts. The wet pelleted fibrils were pipetted in a
2 mm space between two fire-polished glass rods and
allowed to dry. Diffraction patterns were collected using a
Rigaku MicroMax-007HF copper anode X-ray source and
a Rigaku Saturn 944+ CCD detector.
Results and discussion
Two set of constructs for each species were used to evalu-
ate the effect of QSOX co-expression in increasing the
solubility of PrP: full-length MoPrP(23-230), HuPrP(23-
231), truncated MoPrP(89-230) and HuPrP(90-231). The
constructs were cloned into pET28a plasmid, while the
QSOX gene was expressed in a pTRC-HisA vector. Both
plasmids are IPTG inducible for simultaneous expression
of both proteins. We evaluated the expression level and
solubility of each construct on SDS-PAGE and immuno-
blot with anti-His-tag antibody (Figure 1). In addition, we
examined protein expression and solubility of MoPrP(89-
230) in the presence and absence of QSOX at various time
points after induction in standard LB broth. After
induction, cells expressing both proteins showed a reduced
growth rate compared to the one expressing only MoPrP
(89-230) (Figure 2A), which is probably an effect of the
metabolic burden imposed by the double recombinant
proteins over-expression [24]. Immunoblot analysis using
anti-His-tag specific antibodies on total cell extracts
showed that the total production of MoPrP(89-230) dur-
ing the first three hours of the induction is equivalent
between cells with or without QSOX. However, after three
hours of induction a difference in total PrP production
between both cells is observed. In cells without QSOX, the
total concentration of PrP decreased compared to cells
with QSOX, where the PrP concentration remained con-
stant over time (Figure 2B, C, D). Expression of PrP with-
out QSOX is known to produce insoluble recombinant
protein [8], hence the decrease in PrP concentration could
be attributed to the degradation of the insoluble fraction
by cytoplasmic proteases [25]. We further estimated the
quantity of soluble MoPrP(89-230) during the course of
the induction (Figure 2E, F). In absence of QSOX, no solu-
ble PrP is present in the cell extracts throughout the 16
hours of induction, while in presence of QSOX, soluble
PrP can be detected after two hours induction. The
Figure 1 Effect of the co-expression of QSOX on the expression of soluble PrP in the cytoplasm of E. coli. A) SDS-PAGE analysis of MoPrP
(89-230). Expression trials in presence of QSOX: Lane 1 = total E. coli lysate, Lane 2 = insoluble fraction, Lane 3 = soluble fraction. Expression trials in
absence of QSOX: Lane 4 = total E. coli lysate, Lane 5 = insoluble fraction, Lane 6 = soluble fraction. The black arrow indicates the MoPrP(89-230).
The corresponding immunoblot using anti-His-tag antibody is shown underneath the SDS-PAGE gel. B) SDS-PAGE and immunoblot analysis of
HuPrP(90-231). C) SDS-PAGE and immunoblot analysis of MoPrP(23-230). D) SDS-PAGE and immunoblot analysis of HuPrP(23-231).
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quantity of PrP in the soluble fraction increased until it
reached a plateau after 16 hours of induction. The soluble
recombinant PrP has been purified by Immobilized Metal
Affinity Chromatography (IMAC), followed by a size
exclusion chromatography to high purity (Figure 3). The
yields per litre of culture after purification were 1 mg/L
for MoPrP(23-230) and 9 mg/L for MoPrP(89-230). For
the human PrP, the yield was 1.5 mg/L for HuPrP(23-231)
and 3 mg/L for HuPrP(90-231). Attempts to produce solu-
ble PrP with commercially available chaperones like DnaK,
DnaJ, GrpE, GroES, GroEL failed (data not shown).
In the next step, we evaluated the structure of the differ-
ent PrP construct co-expressed with QSOX with far-UV
circular dichroism (CD) and nuclear magnetic resonance
(NMR) spectroscopy. All CD spectra show a double mini-
mum at 208 and 222 nm, characteristic for a-helical pro-
teins, indicating that all four PrP contain a significant
amount of secondary structure (Figure 4A). Moreover, the
1D 1H NMR spectra showed that all soluble expressed PrP
are well folded (Figure 4B). Previous studies on PrP showed
that the presence of a disulfide bond is essential to main-
tain the a-helical fold of the C-terminal end [12]. There-
fore, we verified whether the disulfide is formed in soluble
expressed PrP using a Thiostar assay [22] (Figure 5). No
free thiols were found in soluble expressed PrP, confirming
that a disulfide bond is indeed formed upon expression in
the cytoplasm.
In order to explore in detail the structure of the soluble
mouse PrP, uniformly 15N-13C-labelled MoPrP(89-230)
was produced in co-expression with QSOX. 1H-15N
HSQC spectra are characteristic for a well-folded protein
with no tendency for aggregation at both pH 4.6 and pH
7.0 (Figure 6A). Backbone assignments at pH 4.6 are
essentially complete (≈ 96%), except for the ten N-term-
inal residues that include the hexahistidine tag. Most
importantly, the Cb chemical shifts of Cys179 and
Cys214 are indicative for a disulfide bond between the
two cysteines, concurring with the Thiostar assay. The
consensus chemical shift index (CSI) [26] indicates the
presence of three a-helices (144-154), (177-193), and
(200-227). The CSI also suggests that regions (128-131)
and (160-164) show some propensity for b-strand confor-
mation (Figure 6B). A preliminary three-dimensional
model of MoPrP(89-230) was generated from the 1H,
13C, and 15N backbone chemical shifts using CS23D2.0
[21]. The resulting three-dimensional model exhibits
mainly an a-helical structure with three a-helices dis-
playing an orientation similar to the previous structure of
MoPrP(121-231) [27]. Alignment of the two structures
suggests that a2 and a3 helices in our model are slightly
more elongated (Figure 7). Interestingly, a3 in our model
forms a regular a-helix from E200 to G227, with no
break between Q219 and S222 as observed in the NMR
structure of the refolded MoPrP(121-231) [27]. 1H-15N
Figure 2 Production of MoPrP(89-230) in E. coli. A) Growth curve
of E. coli cells, showing the expression of MoPrP(89-230): absence of
QSOX and co-expressed with QSOX in black and in red respectively.
B) SDS-PAGE of total cell extract. Lane 1: (+) QSOX before induction,
lane 2: (-) QSOX before induction, 3: (+) QSOX 1 h after induction,
lane 4: (-) QSOX 1 h after induction, lane 5: (+) QSOX 2 h after
induction, lane 6: (-) QSOX 2 h after induction, lane 7: (+) QSOX 4 h
after induction, lane 8: (-) QSOX 4 h after induction, lane 9: (+)
QSOX 8 h after induction, lane 10: (-) QSOX 8 h after induction, lane
11: (+) QSOX 16 h after induction, lane 12: (-) QSOX 16 h after
induction and lane 13: MW. C) Immunoblot showing the expression
level of total MoPrP(89-230) over time. D) Quantification of the total
production of MoPrP(89-230) expressed over 16 h. Intensities from
the western blot signal were quantified using the LabImage
software, in presence of QSOX and in absence of QSOX in red and
green respectively. E) Immunoblot showing the expression level of
soluble MoPrP(89-230) over time (same time points as in B). F)
Quantification of the production of soluble MoPrP(89-230) expressed
over 16 h, in presence of QSOX and in absence of QSOX in red and
green respectively.
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Figure 3 Purification of soluble MoPrP(89-230). A) Purification of MoPrP(89-230) after Ni-NTA. Lane 1: Molecular weight. Lane 2: Lysate
(soluble fraction). Lane 3: Flow through. Lane 4 to 9: Elution peak. B) Size exclusion chromatogram (Superdex75 HR10/30). C) SDS/PAGE of
pooled fractions from the highest elution peak (from 13 to 16 mL elution volume). Lane 1: Molecular weight. Lane 2: pooled fractions contain
purified PrP.
Figure 4 Biophysical characterisation of the four soluble PrP. A) Far-UV CD spectra of the four soluble PrP collected at 25°C in sodium
acetate buffer pH 4.6. MoPrP(23-230) in red, HuPrP(23-231) in blue, MoPrP(89-230) in black and HuPrP(90-231) in green. B) 1D 800 MHz 1H-
NMR spectra of the soluble PrP: (a) MoPrP(89-230), (b) MoPrP(23-230), (c) HuPrP(90-231) and (d) HuPrP(23-231). All spectra were recorded at
25°C, pH 4.6.
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Figure 5 Thiostar assay for soluble and refolded MoPrP(89-230). Fluorescence of free thiols in soluble and refolded PrP (5 μM) compared to
reduced L-glutathione (0 μM, 10 μM, 20 μM, 30 μM, 40 μM, 50 μM and 60 μM).
Figure 6 NMR spectra and Chemical Shift Index for MoPrP(89-230). A) 800 MHz 1H-15N HSQC at pH 4.6 and pH 7.0 recorded at 25°C. B)
Chemical Shift Index (CSI) at pH 4.6 with the secondary structure prediction based on the backbone chemical shifts. The primary sequence of
MoPrP(89-230) is shown on the top.
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heteronuclear NOEs measured in MoPrP(89-230) show
no significant variations within the (200-227) region with
an average value of 0.8 indicative of restricted motions
along the a3 helix (Figure 8). The structure of the
refolded MoPrP(121-231) exhibits a b-sheet between 128
to 130 and from 161 to 163 [27]. Although this b-sheet is
not proposed in the model of MoPrP(89-230) generated
with CS23D2.0, manual analysis of 15N-NOESY-HSQC
and 13C-NOESY-HSQC spectra allowed the identification
of specific long range NH-NH and CHa-CHa NOEs
between the residues 127 to 130 and 161 to 164 (data not
shown) supporting the formation of the antiparallel b-
sheet present in the soluble MoPrP(89-230) protein.
We have also tested if the soluble MoPrP(89-230) can
form fibrils. It is commonly accepted in the prion biology
field that PrP amyloid fibrils generated in vitro can be
used as a synthetic surrogate for PrPSc [23]. We gener-
ated in vitro the amyloid aggregates using the soluble
MoPrP(89-230) because this truncated MoPrP has been
extensively studied in fibrils studies [23]. To generate in
vitro fibrils we used the amyloid seeding assay (ASA) pro-
tocol, which is a high-throughput technique for prion
fibrils formation in vitro developed in the Prusiner
laboratory. The fibrilization reaction was performed in
quasi-native condition at physiological pH and in the
presence of a low concentration of denaturant (0.4 M
GuHCl). The polymerization process was monitored sim-
ply by applying thioflavin T in the reaction mixture. This
dye shows strong increase of fluorescence upon binding
to b-sheet rich structures like amyloid aggregates. When
Figure 7 Structural superposition of the refolded and soluble MoPrP(89-230) 3D structures. Superimposition was generated with
CS23D2.0 based on the backbone chemical shifts in green and orange respectively shown in two different orientations (A and B). The three
helices a1, a2 and a3 are annotated for each structure. C) The structure of the refolded MoPrP(121-230) coloured in green exhibits a b-sheet
between 128-130 and 161-163. Although this b-sheet is not present in the model of MoPrP(89-230) generated with CS23D2.0, the region Y156-
Q167 that includes the second b-strand 161-163 in the refolded MoPrP(121-230) is well-superimposed with that in MoPrP(89-230) as highlighted
by the blue circle.
Figure 8 Plots of the 1H-15N NOEs versus the residue numbers of MoPrP(89-230). A schematic of the secondary structure of MoPrP(89-230)
is shown above the graph.
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used in conjunction with multi-well plates and auto-
mated fluorescence plate readers, the ThT represents a
feasible, highly sensitive, high-throughput approach for
the detection of conformational changes of proteins. In
our experiments we observed a strong increase in fluor-
escence, which corresponds to the ThT binding to b-
sheet rich structures like amyloid aggregates (Figure 9).
Our results are consistent with previous fibrilization
experiments performed with MoPrP(89-230) expressed
in E. coli as inclusion bodies [28,29] and provide a good
indication about the ability of soluble MoPrP(89-230) to
form ThT-positive fibrils. Furthermore, to gain insight
into the morphology and structure of amyloid fibrils
formed using solubly expressed MoPrP(89-230) we per-
formed atomic force microscopy and X-ray fibril diffrac-
tion (Figure 10). The observed fibrils were hundreds of
nanometers in length and had a measured height and
width of approximately 5 nm. Their diffraction pattern
shows reflections at 4.7 Å and ~10 Å, characteristic of
the cross-b pattern previously observed for fibrils formed
by refolded recombinant PrP90-231 [30] and as well as
other amyloidogenic proteins [31].
Conclusion
The formation of the disulfide bond between Cys179 and
Cys214 is essential to obtain a correctly folded PrP [12,32].
Figure 9 Kinetics of MoPrP(89-230) produced in the ASA. A) Kinetic of ThT positive MoPrP(89-230) aggregate. This sigmoidal curve is typical
of an increased content of b-sheet structures together with enhanced aggregation of MoPrP(89-230). B) Mean values of the lag phase. C) Mean
value of the maximum ThT intensity under native condition (n = 4).
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The human Quiescin Sulfhydryl OXidase (QSOX) allows
the formation of native disulfide bonds in eukaryotic pro-
teins expressed in the cytoplasm of E. coli [14,33]. We
showed that co-expressing PrP (full-length or truncate
MoPrP and HuPrP) with QSOX produces a significant
amount of correctly folded PrP in the cytoplasm and that
a disulfide bond is present in the purified protein. Previous
studies showed that co-expression with several chaperones
did not succeed in producing reasonable quantities of
soluble PrP [8]. Furthermore, soluble but partially
degraded PrP could only be produced in the periplasm [9].
In E. coli, disulfide bond formation occurs in the periplasm
[34]. Co-expression with QSOX is a good alternative to
produce mammalian proteins containing disulfide bonds
in the E. coli.
To the best of our knowledge, there is no evidence for
direct interaction in vivo of QSOX with the PrP; therefore
we believe that QSOX could be used to express different
mammalian PrP in E. coli. The described method is a sim-
ple and effective method for producing large quantities of
soluble PrP in E. coli, which can subsequently be used for
functional and structural studies.
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